pheniramine
Trade name: Tripoton
Approved
Jul 1, 1948
Pheniramine is an antihistamine used to treat allergic conditions such as hay fever or urticaria. It is generally sold in combination with other medications, rather than as a stand-alone drug. Allergies are caused by an excessive type 1 hypersensitivity response of the body to allergens, mediated by inappropriate histamine signalling. By inhibiting the binding of histamine, antihistamines decrease the normal histamine response from cells, consequently decreasing allergic symptoms. Antihistamines such as pheniramine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine which are mediated through activation of H1- receptor sites and thereby reduce the intensity of allergic reactions and tissue injury response involving histamine release. Antihistamines suppress the histamine-induced wheal (swelling) and flare (vasodilation) response by blocking the binding of histamine to its receptors on nerves, vascular smooth muscle, glandular cells, endothelium, and mast cells. They effectively exert competitive antagonism of histamine for H1-receptors. Pheniramine is marketed under the trade name Avil and Visine-A among others). — NCATS
Clinical trial activity
3 trials · 4 clinical orgs · 7 marketing orgs
Earliest trial started Aug 1, 2011 (NCT01390961)
Timeline
1940s
- Jul 1, 1948
Earliest FDA Approval
1990s
- Jun 8, 1994
Bausch & Lomb — First NDA Organization
- Jun 8, 1994
Alcon — NDA Secondary Org
- Jun 8, 1994
Bausch & Lomb — NDA Secondary Org
- Jun 8, 1994
Nestle — NDA Secondary Org
- Jun 8, 1994
Bausch & Lomb — NDA Organization
- Jan 31, 1996
Johnson and Johnson — NDA Secondary Org
2010s
- Sep 27, 2010
Altair Therapeutics — Marketing Organization
- Jan 1, 2013
Earliest Phase 3 Sponsor(trial)
- Jan 24, 2013
Akorn, Inc. — Marketing Organization
- Jan 24, 2013
Rising Pharmaceuticals — Marketing Organization
Indications
Mechanism of action
- Histamine H1 receptorANTAGONIST
HRH1 antagonist
Combination products
opcon-a
with naphazoline
Also known as naphcon-a, visine
Approval history
- approvedJul 1, 1948
Chemistry & pharmacology
SMILES
CN(C)CCC(c1ccccc1)c1ccccn1- Mol. weight
- 240.35 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
- Delivery
- Topical
- Availability
- Over the Counter
Oral
No
Parenteral
No
Topical
Yes
Sources
- ChEMBLCHEMBL1193 ↗
- WikipediaPheniramine ↗
- NCATS134FM9ZZ6M ↗
- ChEMBLCHEMBL1653 ↗
Also known as
- avil ret
- daneral-sa
- feniramina
- feniramina
- pheniramine
- pheniramine
- pheniramine
- pheniramine
- pheniramine
- pheniramine
- pheniramine
- pheniramine
- pheniramine maleate
- pheniramine maleate
- pheniramine maleate
- pheniramine maleate
- pheniraminum
- pheniraminum
- propheniramine
- propheniramine
- propheniramine
- propheniramine
- propheniramine
- propheniramine
- prophenpyridamine
- pyriton
- trimeton
- trimeton
- tripoton
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02730364 | Phase 3 | Feb 1, 2017 | GlaxoSmithKline |
| NCT01533220 | Phase 3 | Jun 1, 2013 | EMS S/A |
| NCT01390961 | Phase 4 | Aug 1, 2011 | Allergan, Hom, Milton M., OD, FAAO |
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Allergan | For profit | 1 | 0 | 1 | 2011 |
| EMS S/A | For profit | 1 | 1 | 1 | 2013 |
| GlaxoSmithKline | For profit | 1 | 1 | 1 | 2017 |
| Hom, Milton M., OD, FAAO | Academic/Hospital | 1 | 1 | 1 | 2011 |
Marketing (9)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Akorn, Inc. | For profit | SYN | Jan 24, 2013 |
| Akorn, Inc. | For profit | MKTG | Jan 24, 2013 |
| Alcon | For profit | NDA2 | Jun 8, 1994 |
| Altair Therapeutics | For profit | MKTG | Sep 27, 2010 |
| Bausch & Lomb | For profit | NDA2 | Jun 8, 1994 |
| Bausch & Lomb | For profit | NDA | Jun 8, 1994 |
| Johnson and Johnson | For profit | NDA2 | Jan 31, 1996 |
| Nestle | For profit | NDA2 | Jun 8, 1994 |
| Rising Pharmaceuticals | For profit | MKTG | Jan 24, 2013 |